14.63%| YTD | 1Yr | 3Yr | 5Yr | 10Yr | |
| Fund | 14.63 | 24.06 | -0.58 | 5.50 | 8.73 |
| Classification | 14.49 | 18.09 | -2.53 | 2.74 | 5.11 |
| Index (S&P 500) | 20.90 | 21.30 | -6.10 | 0.30 | -0.70 |
| % Rank in Class (1-best,100=worst) | 53 | 11 | 26 | 11 | 7 |
| Investment Objective: | GL Health/Biotech |
|---|---|
| Net Assets ($Mil) | 10,976.20 |
| Inception Date: | 5/23/84 |
| Manager Name, Tenure | Owens/Hynes, 1984 / 2008 |
| Expense Ratio: | 0.29% |
|
Sales Charge:
Load Type:
|
No Load 0.00% 0.00% |
| Company Name | Symbol | % Net Assets |
|---|---|---|
| Schering Plough Corp | SGP | 7.49 |
| Forest Laboratories Inc | FRX | 4.24 |
| Eli Lilly And Co | LLY | 3.86 |
| Astrazeneca Plc | AZNCF | 3.72 |
| Abbott Laboratories | ABT | 3.48 |
| Merck | MRK | 3.46 |
| Wyeth | WYE | 3.26 |
| Roche Holding Ag | RHHVF | 3.03 |
| Mckesson Corp | MCK | 2.83 |
| Astellas Pharma Inc | NA | 2.82 |
| % of Total Holdings | 38.19 | |